Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A289VV1
Fri, 15.12.2023
HAEMATO AG
Delisting of the HAEMATO share to take place from February 2023; price
potential not yet exhausted; GBC-rating and GBC-price target suspended
HAEMATO has announced the termination of the inclusion of the shares in the
open market of 30 November 2023. The shares are to be delisted after expiry
of the notice period, at the latest by the end [ … ]
Wed, 13.12.2023
Haemato AG
First Berlin Equity Research hat ein Research Update zu Haemato AG (ISIN:
DE000A289VV1) veröffentlicht. Analyst Ellis Acklin hat seine bisherige
Buy-Empfehlung und sein bisheriges Kursziel von EUR 34,00 wegen des
bevorstehenden Delistings zurückgenommen.
Zusammenfassung:
Haemato wird die Notierung ihrer Aktien im Open Market der Frank [ … ]
Thu, 30.11.2023
HAEMATO AG
Berlin, November 30, 2023: The Management Board of HAEMATO AG ("Company"; ISIN: DE000A289VV1/ Open Market / Basic Board) has decided today, November 30, 2023, with the approval of the Supervisory Board, to terminate the inclusion of the Company's shares in the Open Market (Basic Board) on the Frankfurt Stock Exchange pursuant to Section 30 of the G [ … ]
Thu, 16.11.2023
HAEMATO AG
HAEMATO AG publishes figures for the third quarter of 2023: Sales increase of around 13% compared to the same period of the previous year, strong increase in EBIT margin and significant increase in operating result:
In the first nine months of the 2023 financial year, preliminary IFRS consolidated sales rose by around 13% to EUR 212.2 [ … ]
Wed, 15.11.2023
HAEMATO AG
Berlin, 15. November 2023 – Due to new findings on changed market conditions, an updated validation of the profitability of the company's own botulinum toxin project was carried out. After reviewing various options, the Executive Board decided today to terminate the cooperation with the Korean manufacturer Huons BioPharma and to discontinue the pr [ … ]
Mon, 18.09.2023
Haemato AG
First Berlin Equity Research hat ein Research Update zu Haemato AG (ISIN:
DE000A289VV1) veröffentlicht. Analyst Ellis Acklin bestätigt seine
BUY-Empfehlung und erhöht das Kursziel von EUR 33,00 auf EUR 34,00.
Zusammenfassung:
Das Sechsmonatsbericht lag nahe an unseren Prognosen und verdeutlichte die
schlankere operative Kostenstr [ … ]
Thu, 14.09.2023
HAEMATO AG
H1 2023: Turnover and EBIT above our expectations; forecasts and target
price slightly raised; BUY rating confirmed
In the first half of 2023, HAEMATO AG achieved a revenue increase of 10.5 %
to € 133.64 million (previous year: € 120.97 million) and thus exceeded our
expectations. This sales development, which is separated accord [ … ]
Thu, 31.08.2023
HAEMATO AG
___________________________________________________________________________
HAEMATO AG publishes figures for the first half of 2023:
Increase in sales of more than 10% compared to the same period last year, further increase in EBIT margin and disproportionate increase in operating result
In the first half of 2023, preliminar [ … ]
Fri, 14.07.2023
HAEMATO AG
- Compulsory manufacturer discounts burden 'Specialty Pharma' segment
- Lifestyle & Aesthetics' segment should grow in 2023; high potentials
available with Botox launch
- Increase in profitability expected
As expected, HAEMATO AG reports a decline in revenue to € 248.14 million
(previous year: € 285.04 million) for the past f [ … ]
Fri, 14.07.2023
HAEMATO AG
- Compulsory manufacturer discounts burden 'Specialty Pharma' segment
- Lifestyle & Aesthetics' segment should grow in 2023; high potentials
available with Botox launch
- Increase in profitability expected
As expected, HAEMATO AG reports a decline in revenue to € 248.14 million
(previous year: € 285.04 million) for the past f [ … ]